Study links mutations in protein to rare blood vessel condition

07/23/2009 | U.S. News & World Report

Canadian researchers said they identified genetic variations in thrombomodulin, a protein that plays a role in blood coagulation and preventing cell damage, that appear to increase the risk of atypical hemolytic-uremic syndrome. The findings could pave the way for treatments for aHUS, a rare blood vessel disorder caused by damage to endothelial cells, the lead researcher said.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC